TEVA's Quality Score fell 3 points on Tue, Nov 10, to 15. Its price broke out of a narrow range (4 chart checks stopped).
Follow TEVA's trial news. Pro members can get an alert when Teva Pharmaceutical Industries files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 390% over three years while the S&P 500 rose 80%.
“AJOVY revenues in our United States segment in 2025 increased by 42% to $295 million, compared to 2024, mainly due to growth in volume.”
| The company | Gross margin up 15.7 points on the year |
| Its score | Up:Excellent or better for 50 days in a row |
| Latest filing | 8-K, Nov 3 |
Teva wins FDA approval for monthly schizophrenia injection Weltruza
TEVA closed +4.7% that day on 2.8x normal volume.
Expected to report Wed Jan 27, before the open
See "Remarks" Mark Sabag sold 46,000 shares on Nov 5. 38 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Excellentfor quality, not price, 6 of 14 chart checks firingWhat the Quality Score means
TEVA is #20 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 20 |
Share count against a year before: TEVA +1.7%, VTRS -1.4%, MRK -1.1%, ALKS +1.7%.
Expected to report Wed Jan 27, before the open (in 78 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $4.4B, 2% less than a year ago.
“Q3 2026 revenues of $4.4 billion , a decrease of 2% year-over-year in both U.S. dollars and local currency terms, reflecting lower global generics revenues, primarily due to increased competition for lenalidomide capsules”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Product | $3.7B | $3.6B | $3.9B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 3)
| Measure | Figure |
|---|---|
| AUSTEDO revenues | $2.55B to $2.65B |
Sales grew 0.7% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 1.2% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 3, 2026 | +3.0% | +3.0% | +5.6% |
| Jul 29, 2026 | +6.3% | +9.6% | +8.7% |
| Apr 29, 2026 | +7.5% | +11.9% | +13.4% |
Sales grew in three of the last seven years, to $17B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 59.8, MACD above signal, above both averages. Not scored.
8 insiders sold $18.4M across 12 filings in the last 6 months. No open-market buys on record. The newest:
One trade disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
“In the United States, we are subject to competition in the generic drug market from domestic and international generic drug manufacturers and brand-name pharmaceutical companies through introduction of next-generation medicines, authorized generics, existing brand equivalents and manufacturers of therapeutically similar drugs.”
TEVA scores 15 today, which Breakaway calls Excellent. It is #20 of 281 in Biotech by Quality Score, with 6 of 14 chart checks firing. Up 390% over three years while the S&P 500 rose 80%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
TEVA scores 15 today, which Breakaway calls Excellent (15 to 19). That is #20 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind TEVA's 15.
8 insiders sold $18.4M across 12 filings in the last 6 months. No open-market buys on record. The newest is Mark Sabag, See "Remarks", who sold $1.9M on Nov 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.